Natera, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

27 Feb 2026

NTRA

10-K: Natera Reports Strong Revenue Growth, Expands Oncology Portfolio

Natera, Inc. reported significant revenue growth in 2025, driven by increased test volumes across its oncology, women's health, and organ health segments, alongside strategic acquisitions and facility expansions.

NASDAQ

28 Feb 2025

NTRA

Natera, INC

10-K: Natera's 2024 10-K Filing: Revenue Surges, Losses Narrow as Genetic Testing Demand Grows

Natera reports significant revenue growth in 2024, driven by increased demand for its genetic testing products, while simultaneously reducing net losses.

NASDAQ

29 Feb 2024

NTRA

Natera, INC

10-K: Natera Reports Strong Revenue Growth in 2023, Net Losses Decrease

Natera, Inc. saw a significant increase in revenue and a decrease in net losses in 2023, driven by growth in its core product offerings.